Europe Prostate Cancer Diagnosis and Therapy Market Research Report Forecast to 2027

Description

Europe Prostate Cancer Diagnosis and Therapy Market Research Report Forecast to 2027

Market Overview

The Europe prostate cancer diagnosis and therapy market was valued at USD 4,002.70 million in 2020 and is expected to register a CAGR of 5.05% during the assessment period. Prostate cancer is a type of cancer that affects only males in the prostate gland cells and is highly treatable in the early stages. There are various approaches to diagnose and treat prostate cancer available in the market.

The Europe prostate cancer diagnosis and therapy market is emerging due to the rising prevalence rate of prostate cancer. The increasing expenditure on oncology medicine research is anticipated to drive the growth of the market during the forecast period. Additionally, the launching of new products will provide growth opportunities for the market in the future. However, the side effects of Therapy and shortage of skilled and experienced oncologists might hamper the market’s growth in the forecast period.

Market Segmentation

Based on stage, the Europe prostate cancer diagnosis and therapy market is segmented into stage I, stage II, stage III, and stage IV. The Europe prostate cancer diagnosis and therapy market is driven due to the increasing consumption of oncogene-activating components such as tobacco and unhealthy lifestyle. Stage II held the largest market in 2020

Based on type, the Europe prostate cancer diagnosis and therapy market is segmented into prostatic adenocarcinoma, small cell carcinoma, and others. The other segment includes squamous cell carcinoma, neuroendocrine tumors, soft tissue sarcoma, and transitional cancer. Prostatic adenocarcinoma holds the largest market size owing to a large patient pool. The other factor contributing to the increase in prostatic cases are aging, smoking, and obesity.

In terms of components, the Europe prostate cancer diagnosis and therapy market is segmented into diagnosis and therapy. The diagnosis segment is further sub-segmented into tissue biopsy, diagnostic imaging, and others. The therapy segment is sub-segmented into chemotherapy, hormonal therapy, and immunotherapy. The diagnostic imaging segment is expected to hold the largest market size by diagnosis method during the forecast period. The Europe prostate cancer diagnosis and therapy market based on end user has been segmented into hospitals & clinics, specialty centers, and others. The others segment includes ambulatory surgical centers and research institutions.

Regional Analysis

The growing aging population, rising prevalence rate of prostate cancer across Europe, and the increasing awareness among the individuals coupled with the various government initiatives to promote the Therapy of prostate cancer in the early stages are some of the prominent factors driving the growth of the Europe prostate cancer diagnosis and therapy market. For instance, as per GLOBOCAN, in 2020, Europe reported 518.11 new prostate cancer cases per 100,000 population. Similarly, according to the European Alliance for Personalized Medicine, the number of men being diagnosed with prostate cancer in Europe has increased over recent years.

Major Players

The market players include Astellas Pharma, Inc., Johnson & Johnson Services, Inc, Bayer AG, Roche Holding AG, Ipsen S.A., Tolmar Inc., Ferring B.V., and Esaote Spa.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 RISING PREVALENCE RATE OF PROSTATE CANCER
4.2.2 INCREASING EXPENDITURE ON ONCOLOGY MEDICINE AND RESEARCH
4.3 RESTRAINTS
4.3.1 SIDE-EFFECTS OF THERAPY
4.3.2 SHORTAGE OF SKILLED AND EXPERIENCED ONCOLOGIST
4.4 OPPORTUNITY
4.4.1 LAUNCH OF INNOVATIVE THERAPY PRODUCTS
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE EUROPE PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON PATIENTS SUFFERING FROM PROSTATE CANCER
5.3.3 IMPACT ON PRICING
5.3.4 IMPACT ON CLINICAL TRIALS
6 EUROPE PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY STAGES
6.1 OVERVIEW
6.2 STAGE I
6.3 STAGE II
6.4 STAGE III
6.5 STAGE IV
7 EUROPE PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY TYPE
7.1 OVERVIEW
7.2 PROSTATIC ADENOCARCINOMA
7.3 SMALL CELL CARCINOMA
7.4 OTHERS
8 EUROPE PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY COMPONENT
8.1 OVERVIEW
8.2 THERAPY
8.2.1 HORMONAL THERAPY
8.2.2 CHEMOTHERAPY
8.2.3 RADIOTHERAPY DRUGS
8.2.4 IMMUNOTHERAPY
8.2.5 OTHERS
8.3 DIAGNOSIS
8.3.1 DIAGNOSTIC IMAGING
8.3.2 TISSUE BIOPSY
8.3.3 OTHERS
9 EUROPE PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY END USER
9.1 OVERVIEW
9.2 SPECIALTY CENTERS
9.3 HOSPITALS & CLINICS
9.4 OTHERS
10 EUROPE PROSTATE CANCER DIAGNOSIS AND THERAPY MARKET, BY REGION/COUNTRY
10.1 OVERVIEW
10.2 WESTERN EUROPE
10.2.1 GERMANY
10.2.2 FRANCE
10.2.3 UK
10.2.4 ITALY
10.2.5 SPAIN
10.2.6 REST OF WESTERN EUROPE
10.3 EASTERN EUROPE
10.3.1 HUNGARY
10.3.2 POLAND
10.3.3 RUSSIA
10.3.4 REST OF EASTERN EUROPE
10.4 REST OF EUROPE
11 COMPETITIVE LANDSCAPE
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
11.6.2 EXPANSION
11.7 FINANCIAL MATRIX
11.7.1 SALES (USD MILLION), 2020
11.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2020
12 COMPANY PROFILES
12.1 ABBVIE INC.
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS/SERVICES OFFERED
12.1.4 PRODUCTS/SERVICES OFFERED
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 ASTRAZENECA
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS/SERVICES OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGIES
12.3 BAYER AG
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS/SERVICES OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 SWOT ANALYSIS
12.3.6 KEY STRATEGIES
12.4 SANOFI
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS/SERVICES OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 SWOT ANALYSIS
12.4.6 KEY STRATEGIES
12.5 IPSEN S.A.
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS/SERVICES OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 SWOT ANALYSIS
12.5.6 KEY STRATEGIES
12.6 ASTELLAS PHARMA INC.
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS/SERVICES OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 SWOT ANALYSIS
12.6.6 KEY STRATEGIES
12.7 FERRING PHARMACEUTICALS
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS/SERVICES OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 SWOT ANALYSIS
12.7.6 KEY STRATEGIES
12.8 TOLMAR PHARMACEUTICALS, INC.
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS/SERVICES OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 SWOT ANALYSIS
12.8.6 KEY STRATEGIES
12.9 JOHNSON & JOHNSON SERVICES INC.
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS/SERVICES OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 SWOT ANALYSIS
12.9.6 KEY STRATEGIES
12.10 ESAOTE SPA
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS/SERVICES OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 KEY STRATEGIES
12.11 F. HOFFMANN-LA ROCHE LTD
12.11.1 COMPANY OVERVIEW
12.11.2 FINANCIAL OVERVIEW
12.11.3 PRODUCTS/SERVICES OFFERED
12.11.4 KEY DEVELOPMENTS
12.11.5 SWOT ANALYSIS
12.11.6 KEY STRATEGIES
13 APPENDIX
13.1 REFERENCES
13.2 RELATED REPORTS